TABLE 1.

Pharmacological targeting of DDR factors.

Target	Compound	Stage	References
ATM	KU55933	Preclinical	Hickson et al., 2004
	KU60019	Preclinical	Golding et al., 2009
	CP466722	Preclinical	Rainey et al., 2008
	Caffeine	Preclinical	Blasina et al., 1999
	Wortmannin	Preclinical	Sarkaria et al., 1998
	TPA	Preclinical	Truman et al., 2005
	Vitamin B3	Phase 2	NCT03962114
RNF8	Corilagin	Preclinical	Qiu et al., 2019
p53	STIMA-1	Preclinical	Zache et al., 2008
	APR-246	Preclinical	Bykov et al., 2002; Bykov et al., 2005b
	CP-31398	Preclinical	Foster et al., 1999
	MIRA-1	Preclinical	Bykov et al., 2005a
	RITA	Preclinical	Issaeva et al., 2004; Jones et al., 2012
IRE1	B-109	Preclinical	Tang et al., 2014
	STF-083010	Preclinical	Chen et al., 2018
	KIRA6–8	Preclinical	Ghosh et al., 2014; Morita et al., 2017
	Toyocamycin	Preclinical	Ri et al., 2012
	Doxorubicin	Preclinical	Jiang et al., 2016
PERK	GSK2606414	Preclinical	Mercado et al., 2018
	GSK2656157	Preclinical	Atkins et al., 2013
ATF6	Ceapin-A7	Preclinical	Gallagher and Walter, 2016
	PBA	Early Phase 1	NCT04041232